9 March 2018

Additional Financial Information on Segment Results for the half year ended 31 December 2017

pdf-icon-small

Adelaide, Australia 9 March 2018 – Ellex Medical Lasers Limited (ASX:ELX), a global leader in medical devices for the diagnosis and treatment of eye disease, today provided detailed information on the profit and loss for each business segment. This provides investors with greater understanding of the investment being made in Ellex iTrack™ sales and marketing and the impact on the financial results. This information is attached and can be read in conjunction with the consolidated financial results for the half year ended 31 December 2017 issued on 27 February 2018.

View the profit and loss statement here

 


ABOUT ELLEX

Ellex designs, develops, manufactures and sells innovative products that help eye surgeons around the world to effectively and efficiently treat eye disease. Ellex is a world leader in this field. Headquartered in Adelaide, Australia, Ellex has ophthalmic lasers and devices that treat glaucoma, retinal disease primarily caused by diabetes, secondary cataract and vitreous opacities, as well as age-related macular degeneration. Manufacturing is carried out in Adelaide, Australia and Fremont, California. Sales and service directly to eye surgeons is conducted via subsidiary offices in Fremont, Minneapolis, Lyon, Berlin and Tokyo. A network of more than 50 distribution partners around the world services other markets.

For further information on Ellex please contact: Tom Spurling, CEO

Ellex Medical Lasers Limited

3 Second Avenue, Mawson Lakes, SA, 5095

W +61 8 7074 8293 | M +61 417 818 658

tspurling@ellex.com

Mark Lindh, Investor Relations & Corporate

W +61 8 87074 8200 | M +61 414 551 361

mlindh@ellex.com

Maria Maieli, CFO & Company Secretary

Ellex Medical Lasers Limited

3 Second Avenue, Mawson Lakes, SA, 5095

W +61 8 7074 8200

mmaieli@ellex.com